cisplatin + fluorouracil + hydroxyurea + interferon alfa-2a

A combination chemotherapy regimen consisting of cisplatin, fluorouracil (5-FU), hydroxyurea, and interferon alfa-2a, often administered with concurrent radiation therapy. This intensive treatment approach is primarily used for advanced head and neck cancers, particularly squamous cell carcinomas. The regimen typically involves cisplatin (100 mg/m²) every 28 days, fluorouracil (800 mg/m²/day) as continuous infusion for 5 days, hydroxyurea (1g orally every 12 hours for 11 doses), and interferon alfa-2a, with concurrent twice-daily radiation therapy. This combination has demonstrated high rates of locoregional control and survival with organ preservation, though it is associated with significant acute toxicities including mucositis, neutropenia, and thrombocytopenia.